Search Results - "LEONARDI, Craig L"

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) by Mrowietz, Ulrich, MD, Leonardi, Craig L., MD, Girolomoni, Giampiero, MD, Toth, Darryl, MD, FRCPC, Morita, Akimichi, MD, Balki, Shyamal A., FCPS, Szepietowski, Jacek C., MD, Regnault, Pascaline, PhD, Thurston, Helen, MSc, Papavassilis, Charis, MD

“…Background Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52 weeks on a fixed-interval regimen. Objective We sought to compare a…”
Get full text

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis by Gordon, Kenneth B, Blauvelt, Andrew, Papp, Kim A, Langley, Richard G, Luger, Thomas, Ohtsuki, Mamitaro, Reich, Kristian, Amato, David, Ball, Susan G, Braun, Daniel K, Cameron, Gregory S, Erickson, Janelle, Konrad, Robert J, Muram, Talia M, Nickoloff, Brian J, Osuntokun, Olawale O, Secrest, Roberta J, Zhao, Fangyi, Mallbris, Lotus, Leonardi, Craig L

“…In three phase 3 trials, ixekizumab, an anti–IL-17A monoclonal antibody, was effective in the treatment of patients with moderate-to-severe plaque psoriasis…”
Get full text

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis by van de Kerkhof, Peter C.M., MD, PhD, Griffiths, Christopher E.M., MD, Reich, Kristian, MD, PhD, Leonardi, Craig L., MD, Blauvelt, Andrew, MD, MBA, Tsai, Tsen-Fang, MD, Gong, Yankun, PhD, Huang, Jiaqing, MD, PhD, Papavassilis, Charis, MD, PhD, Fox, Todd, RPh, PharmB, ACPR

“…Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe plaque…”
Get full text

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) by Papp, Kim, MD, PhD, Reich, Kristian, MD, PhD, Leonardi, Craig L., MD, Kircik, Leon, MD, Chimenti, Sergio, MD, Langley, Richard G.B., MD, Hu, ChiaChi, EdM, MS, Stevens, Randall M., MD, Day, Robert M., PhD, Gordon, Kenneth B., MD, Korman, Neil J., MD, PhD, Griffiths, Christopher E.M., MD, FMedSci

“…Background Apremilast works intracellularly to regulate inflammatory mediators. Objective ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day…”
Get full text

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis by Sofen, Howard, MD, Smith, Stacy, MD, Matheson, Robert T., MD, Leonardi, Craig L., MD, Calderon, Cesar, PhD, Brodmerkel, Carrie, PhD, Li, Katherine, MS, Campbell, Kim, PhD, Marciniak, Stanley J., MBA, Wasfi, Yasmine, MD, PhD, Wang, Yuhua, PhD, Szapary, Philippe, MD, Krueger, James G., MD, PhD

“…Background IL-23 expression is increased in psoriatic lesions and might regulate TH 17 T-cell counts in patients with psoriasis. Objectives We sought to test a…”
Get full text

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) by Leonardi, Craig L, Prof, Kimball, Alexa B, MD, Papp, Kim A, MD, Yeilding, Newman, MD, Guzzo, Cynthia, MD, Wang, Yuhua, PhD, Li, Shu, MS, Dooley, Lisa T, DrPH, Gordon, Kenneth B, Dr

“…Summary Background Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody…”
Get full text

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial by Menter, Alan, MD, Tyring, Stephen K., MD, PhD, MBA, Gordon, Kenneth, MD, Kimball, Alexa B., MD, MPH, Leonardi, Craig L., MD, Langley, Richard G., MD, Strober, Bruce E., MD, PhD, Kaul, Martin, MD, Gu, Yihua, MS, Okun, Martin, MD, PhD, Papp, Kim, MD

“…Background Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of…”
Get full text

Guidelines of care for the management of psoriasis and psoriatic arthritis by Menter, Alan, MD, Korman, Neil J., MD, PhD, Elmets, Craig A., MD, Feldman, Steven R., MD, PhD, Gelfand, Joel M., MD, MSCE, Gordon, Kenneth B., MD, Gottlieb, Alice, MD, PhD, Koo, John Y.M., MD, Lebwohl, Mark, MD, Leonardi, Craig L., MD, Lim, Henry W., MD, Van Voorhees, Abby S., MD, Beutner, Karl R., MD, PhD, Ryan, Caitriona, MB, BCh, BAO, Bhushan, Reva, PhD

“…Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the…”
Get full text

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis by Gordon, Kenneth B., MD, Leonardi, Craig L., MD, Lebwohl, Mark, MD, Blauvelt, Andrew, MD, MBA, Cameron, Gregory S., PhD, Braun, Daniel, MD, PhD, Erickson, Janelle, PhD, Heffernan, Michael, MD

“…Background Patients with moderate to severe plaque psoriasis demonstrated positive responses to ixekizumab, an anti-interleukin-17A monoclonal antibody, in a…”
Get full text

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis by Harden, Jamie L., PhD, Johnson-Huang, Leanne M., PhD, Chamian, Maria Francesca, MD, Lee, Edmund, MD, Pearce, Tillman, MD, Leonardi, Craig L., MD, Haider, Asifa, PhD, Lowes, Michelle A., MD, PhD, Krueger, James G., MD, PhD

Get full text

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis by Menter, Alan, MD, Gordon, Kenneth B., MD, Leonardi, Craig L., MD, Gu, Yihua, MS, Goldblum, Orin M., MD

“…Background The phase III r andomized controlled ev aluation of adalimumab e very other week dosing in moderate to severe psoriasis tri al (REVEAL) demonstrated…”
Get full text

Research gaps in psoriasis: Opportunities for future studies by Ryan, Caitriona, MD, Korman, Neil J., MD, PhD, Gelfand, Joel M., MD, MSCE, Lim, Henry W., MD, Elmets, Craig A., MD, Feldman, Steven R., MD, PhD, Gottlieb, Alice B., MD, PhD, Koo, John Y.M., MD, Lebwohl, Mark, MD, Leonardi, Craig L., MD, Van Voorhees, Abby S., MD, Bhushan, Reva, PhD, Menter, Alan, MD

“…Over the past 2 decades, considerable progress has been made to further elucidate the complex pathogenesis of psoriasis, facilitating the development of a new…”
Get full text

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis by Pariser, David M., MD, Leonardi, Craig L., MD, Gordon, Kenneth, MD, Gottlieb, Alice B., MD, PhD, Tyring, Stephen, MD, PhD, Papp, Kim A., MD, Li, Joanne, PhD, Baumgartner, Scott W., MD

“…Background Multiple trials demonstrate the tolerability and safety of etanercept. However, there are limited data on etanercept tolerability in large…”
Get full text

Clinical Goals and Barriers to Effective Psoriasis Care by Strober, Bruce E., van der Walt, Joelle M., Armstrong, April W., Bourcier, Marc, Carvalho, Andre V. E., Chouela, Edgardo, Cohen, Arnon D., de la Cruz, Claudia, Ellis, Charles N., Finlay, Andrew Y., Gottlieb, Alice B., Gudjonsson, Johann E., Iversen, Lars, Kleyn, C. Elise, Leonardi, Craig L., Lynde, Charles W., Ryan, Caitriona, Theng, Colin T., Valenzuela, Fernando, Vender, Ronald, Wu, Jashin J., Young, Helen S., Kimball, Alexa B.

“…Engaging global key opinion leaders, the International Psoriasis Council (IPC) held a day-long roundtable discussion with the primary purpose to discuss the…”
Get full text

Wolf’s isotopic response of lichen planus following contact dermatitis by Pollard, Bruin, McCoy, William H., Leonardi, Craig L., Martin, Ann G.

Get full text

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) by Gottlieb, Alice B., Blauvelt, Andrew, Thaçi, Diamant, Leonardi, Craig L., Poulin, Yves, Drew, Janice, Peterson, Luke, Arendt, Catherine, Burge, Daniel, Reich, Kristian

“…Certolizumab pegol, the only Fc-free, PEGylated anti–tumor necrosis factor biologic, demonstrated clinically meaningful improvements suggestive of a positive…”
Get full text

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial by Blauvelt, Andrew, Leonardi, Craig L, Gooderham, Melinda, Papp, Kim A, Philipp, Sandra, Wu, Jashin J, Igarashi, Atsuyuki, Flack, Mary, Geng, Ziqian, Wu, Tianshuang, Camez, Anne, Williams, David, Langley, Richard G

“…Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to psoriatic inflammation. To evaluate the efficacy and safety of risankizumab vs…”
Get more information

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics by Menter, Alan, Strober, Bruce E., Kaplan, Daniel H., Kivelevitch, Dario, Prater, Elizabeth Farley, Stoff, Benjamin, Armstrong, April W., Connor, Cody, Cordoro, Kelly M., Davis, Dawn M.R., Elewski, Boni E., Gelfand, Joel M., Gordon, Kenneth B., Gottlieb, Alice B., Kavanaugh, Arthur, Kiselica, Matthew, Korman, Neil J., Kroshinsky, Daniela, Lebwohl, Mark, Leonardi, Craig L., Lichten, Jason, Lim, Henry W., Mehta, Nehal N., Paller, Amy S., Parra, Sylvia L., Pathy, Arun L., Rupani, Reena N., Siegel, Michael, Wong, Emily B., Wu, Jashin J., Hariharan, Vidhya, Elmets, Craig A.

“…Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions…”
Get full text

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) by Kalb, Robert E, Fiorentino, David F, Lebwohl, Mark G, Toole, John, Poulin, Yves, Cohen, Arnon D, Goyal, Kavitha, Fakharzadeh, Steven, Calabro, Stephen, Chevrier, Marc, Langholff, Wayne, You, Yin, Leonardi, Craig L

“…The efficacy of treatment for psoriasis must be balanced against potential adverse events. To determine the effect of treatment on the risk of serious…”
Get more information

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities by Elmets, Craig A., Leonardi, Craig L., Davis, Dawn M.R., Gelfand, Joel M., Lichten, Jason, Mehta, Nehal N., Armstrong, April W., Connor, Cody, Cordoro, Kelly M., Elewski, Boni E., Gordon, Kenneth B., Gottlieb, Alice B., Kaplan, Daniel H., Kavanaugh, Arthur, Kivelevitch, Dario, Kiselica, Matthew, Korman, Neil J., Kroshinsky, Daniela, Lebwohl, Mark, Lim, Henry W., Paller, Amy S., Parra, Sylvia L., Pathy, Arun L., Prater, Elizabeth Farley, Rupani, Reena, Siegel, Michael, Stoff, Benjamin, Strober, Bruce E., Wong, Emily B., Wu, Jashin J., Hariharan, Vidhya, Menter, Alan

“…Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions…”
Get full text